Cashu
Jazz Pharmaceuticals Partners with Saniona to Enhance Epilepsy Treatment Portfolio
18 days ago
Stocks
Health Care
jazz
Jazz Pharmaceuticals plc
NASDAQ: JAZZ
-1.29 (-0.99%)
128.56
USD
At close at Sep 09, 20:37 UTC
Overview
Loading chart...
Key Stats
Market Cap
7.92B
Dividend Yield
0.00%
P/E Ratio
-19.57
EPS
9.08
Revenue
4.07B
Avg. Volume
681.82K
About
What does JAZZ do?
Jazz Pharmaceuticals Plc, headquartered in Dublin, focuses on developing treatments for narcolepsy, oncology, pain, and psychiatry, employing 2,800 staff since its IPO in 2012. Key products include Xywav, Xyrem, and Defitelio.
Join our newsletter to keep up to date with us!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.